-
s Benefits of Statins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitors for Patients with Peripheral Arterial Disease
- Source: Current Vascular Pharmacology, Volume 22, Issue 1, Jan 2024, p. 8 - 10
-
- 01 Jan 2024
Preview this article:
Benefits of Statins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitors for Patients with Peripheral Arterial Disease, Page 1 of 1
< Previous page Next page > /docserver/preview/fulltext/cvp/22/1/s4-1.gifThere is no abstract available.
© Bentham Science Publishers